-- Docebo (DCBO.TO, DCBO) reported improved adjusted earnings and revenues for the first quarter, and while the company flagged lower than forecast revenues for the second quarter, it lifted its own expectations for them over the full year.
For the three months ended March 31, 2026, the company reported net loss of US$1.6 million, compared with net income of $1.5 million a year earlier. But it reported in line adjusted EPS diluted of US$0.34, higher than the $0.32 seen.
Total revenue increased to US$65.6 million compared with $57.3 million, a year-ago, in line with a consensus estimate compiled by FactSet of US$65.7 million. Subscription revenue increased 12% to US$60.6 million in the quarter from the comparative prior-year period.
For Q2, the company expects total revenue to be between US$66.7 million and $66.9 million, below a FactSet consensus forecast of $67.2 million, and adjusted EBITDA between $10.9 million to $11.1 million.
Subscription revenue in Q2 is expected to be in-line with total revenue growth, Docebo said.
For the fiscal year ending Dec. 31, 2026, subscription revenue is expected to be between US$253.5 million and $255.5 million, total revenue between $271.0 million and $273.0 million and adjusted EBITDA between $54.5 million and $56.5 million. For full year total revenues, the consensus forecast at Docebo is $272.3 million, while the company's previous guidance was for between $267.5 million to $269.5 million, as noted by The Wall Street Journal.
The Toronto Stock Exchange also approved the company's notice of intention to renew its normal course issuer bid (NCIB) for its common shares, it added. Pursuant to the notice, Docebo is authorized to buy back up to a maximum of 1.3-million shares, or 5% of its 25.4-million issued and outstanding shares as of May 6, for cancellation over the next 12 months.
Docebo may begin to purchase shares on or about May 20, 2026, and the bid will cancel on May 19, 2027, or such earlier time as Docebo completes its purchases pursuant to the bid or provides notice of termination. The company also renewed its automatic securities purchase plan with its designated broker to facilitate the purchase of shares under the NCIB at times when Docebo would ordinarily not be permitted to purchase shares due to regulatory restrictions or self-imposed blackout periods.
U.S.-listed shares of the company were last seen up 2.8% at US$21.55 in pre-market trading.